09:51 AM EDT, 06/02/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Monday presented data in three clinical poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Highlights include data from the Bria-IMT Phase 2 study showing heavily pre-treated patients treated since 2022 with a median survival range of between 13.9 months to 17.3 months.

"We are thrilled with our Phase 2 overall survival and clinical benefit data which meets and exceeds those of FDA approved drugs - even in very heavily pre-treated patients in our study," said Chief Executive Dr. William Williams in a statement.

The company also noted the low incidence of all grade and grade 3/4 adverse events.

The company's shares were last seen up $0.06, to $4.70, on the Toronto Stock Exchange.

Price: 4.70, Change: +0.06, Percent Change: +1.29